Last reviewed · How we verify
LINQ for impEdance meAsuremeNt While Off From HF Medication Study (LEAN HF)
The purpose of this non-randomized, cross-over, unblinded, single-center feasibility study is to assess the sensitivity of the LINQ ICM to measure derived-subcutaneous impedance in patients with heart failure during periods when diuretics and/or HF-medication consumption is increased or suspended for 48 hours (up to 72 hours at physician discretion) and to collect safety information related to HF status and to medication consumption changes.
Details
| Lead sponsor | Medtronic BRC |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 30 |
| Start date | 2017-10-30 |
| Completion | 2019-04 |
Conditions
- Heart Failure
Interventions
- Diuretic Suspension (DS)
- Diuretic Increase (DI)
- Diuretic and Medication Suspension (DMS)
Primary outcomes
- Derived-subcutaneous impedance — 2 months
The variation of impedance magnitude and the time of occurrence after medication regimen changes will be detected by the LINQ ICM
Countries
United Kingdom